University of Ioannina
Μελέτη των επιδράσεων της προλακτίνης και συγγενών ορμονών σε ορμονοεξαρτώμενες κυτταρικές σειρές του μαστού και του προστάτη
Abstract
dc:descriptionBreast cancer is the second most common cause of cancer death among women, while prostate cancer is the second leading cause of cancer death among men in most Western countries. Both diseases have some common characteristics such as their hormone dependence. Prolactin is a hormone that participates in some degree in the pathogenesis of both diseases. There are plenty of experimental and clinical data on the influence of prolactin in breast cancer. Breast cancer cells proliferate faster in the presence of prolactin, while the addition of prolactin antagonists or prolactin variants such as 16 kDa PRL results in inhibition of breast cancer cells’ proliferation. Prolactin influences directly the initiation and progress of breast cancer in rodents, where a direct association between hyperprolactinemia and occurrence of breast tumors has been observed. In rodents prolactin increases also the sensitivity of breast to different chemical carcinogens. In human breast tumors the prolactin receptor is found in the majority of cases and in some studies certain variants of the receptor are encountered in a greater proportion in cancer cells than in normal ones. In breast cancer cells endogenous prolactin is also produced and this ectopically produced PRL may act as a major local growth promoter via autocrine and paracrine mechanisms. In prostate, prolactin seems to plays a role in the development and maintenance of the human prostate and may also participate in the pathogenesis of prostate cancer. Prolactin receptor (PRLR) is present in prostate cancer cells and the hormone exerts a proliferative action that is inhibited in the presence of prolactin antagonists. The presence of prolactin receptors and the endogenous prolactin production in prostate cells shows that prolactin acts as an autocrine/paracrine growth factor in these cells. N-acetylcysteine (NAC) and N-(2-Mercaptopropionyl) glycine (MPG) are sulphydryl compounds that are used in the treatment of some human diseases. They are also antioxidants, and NAC is a precursor of glutathione, which is the most abundant intracellular antioxidant. N-acetylcysteine has been studied extensively as concern as the prevention of several cancers e.g. lung cancer. Experimentally NAC has shown anticancer properties, but in clinical status the results are inconsistent. In the present study the effects of prolactin on breast cancer cells MCF-7 and prostate cancer cells DU-145 have been investigated and its mitogen action has been confirmed. These effects were more obvious and statistically significant at concentrations of 200-400 ng/ml PRL. Consequently, we studied the influence of NAC and MPG on MCF-7 and DU-145 cell proliferation. The results were similar in both cell lines. Particularly NAC at small concentrations increases cell proliferation in both cancer cell lines. This action is of small degree on breast cancer cells and more intense and statistically significant on prostate cancer cells. N-(2-Mercaptopropionyl) glycine at low concentrations increases in a small degree the cell proliferation of MCF-7, while it increases significantly the proliferation of DU-145. Intermediate concentrations of both substances do not affect the proliferation of the above cancer cell lines, and greater concentrations of NAC and MPG inhibit cell proliferation and are toxic for the cells. After that we tested the effect of non-toxic concentration of these compounds on PRL- induced cell proliferation, an action that has not been study till now. We observe that nontoxic concentrations of NAC and MPG inhibit the mitogen effect of prolactin on MCF-7 and DU-145 cells. We investigate furthermore the mechanism of the above-described effects in molecular level as concern as the expression of proteins that regulate the cell cycle. We noticed that the PRL-induced cell proliferation of MCF-7 cells is associated with increased expression of cyclins D1, E, B1, and E2F, while no special differences are observed on p21 and p27 expression. In contrast, the inhibition of prolactin effects is associated with a decreased expression of cyclins and E2F. We consider that more extensive studies are needed to examine the capacity of other sulphydryl compounds to inhibit the mitogenic effect of carcinogens on cancer cell lines, and the possibility of the potential clinical applications of these observations in the future.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2007
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Malamas, Fotodotis
- Μάλαμας, Φωτοδότης
Subjects
dc:subject × 20- Μαστός, Καρκινικά κύτταρα
- Προστάτης, Καρκινικά κύτταρα
- Σουλφυδρυλικές ενώσεις
- Ν-ακετυλοκυστεϊνη (NAC)
- Ν - (2-Μερκαπτοπροπιονυλ) γλυκίνη (MPG)
- Προλακτίνη
- Κυτταρικός πολλαπλασιασμός
- Κυκλίνες
- Breast cancer cells
- Prostate cancer cells
- Sulphydryl compounds
- N-acetyclysteine (NAC)
- N - (2 - Mercaptopropionyl) glycine (MPG)
- Prolactin (PRL)
- Cell proliferation
- Cyclins
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/20600